Is Edwards Lifesciences Stock a Good Investment?
Edwards Lifesciences Investment Advice | EW |
- Examine Edwards Lifesciences' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Edwards Lifesciences' leadership team and their track record. Good management can help Edwards Lifesciences navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Edwards Lifesciences' business and its evolving consumer preferences.
- Compare Edwards Lifesciences' performance and market position to its competitors. Analyze how Edwards Lifesciences is positioned in terms of product offerings, innovation, and market share.
- Check if Edwards Lifesciences pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Edwards Lifesciences' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Edwards Lifesciences Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Edwards Lifesciences Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Edwards Lifesciences Stock
Researching Edwards Lifesciences' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 86.0% of the company shares are held by institutions such as insurance companies. The book value of Edwards Lifesciences was currently reported as 16.18. The company had not issued any dividends in recent years. Edwards Lifesciences Corp had 3:1 split on the 1st of June 2020.
To determine if Edwards Lifesciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Edwards Lifesciences' research are outlined below:
| Over 86.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: EW STOCK REPORT Suffer Losses on Your Edwards Lifesciences Investment Contact BFA Law about ... |
Edwards Lifesciences Quarterly Good Will |
|
Edwards Lifesciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Edwards Lifesciences Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Edwards Lifesciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 24th of April 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Edwards Lifesciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Edwards Lifesciences' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2012-10-19 | 2012-09-30 | 0.09 | 0.1 | 0.01 | 11 | ||
2012-04-24 | 2012-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2011-10-19 | 2011-09-30 | 0.07 | 0.06 | -0.01 | 14 | ||
2010-07-21 | 2010-06-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2009-07-20 | 2009-06-30 | 0.06 | 0.07 | 0.01 | 16 | ||
2009-02-03 | 2008-12-31 | 0.06 | 0.07 | 0.01 | 16 | ||
2008-07-22 | 2008-06-30 | 0.05 | 0.06 | 0.01 | 20 | ||
2008-04-22 | 2008-03-31 | 0.04 | 0.05 | 0.01 | 25 |
Know Edwards Lifesciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Edwards Lifesciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Edwards Lifesciences Corp backward and forwards among themselves. Edwards Lifesciences' institutional investor refers to the entity that pools money to purchase Edwards Lifesciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Brown Advisory Holdings Inc | 2024-09-30 | 7.6 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 7.3 M | Ninety One Uk Limited | 2024-09-30 | 7.3 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 6 M | Amvescap Plc. | 2024-06-30 | 5.9 M | Hhg Plc | 2024-06-30 | 5.4 M | Legal & General Group Plc | 2024-06-30 | 5.4 M | Northern Trust Corp | 2024-09-30 | 5.3 M | Sands Capital Management, Llc | 2024-09-30 | 5.3 M | Vanguard Group Inc | 2024-09-30 | 62.6 M | Blackrock Inc | 2024-06-30 | 51 M |
Edwards Lifesciences' market capitalization trends
The company currently falls under 'Large-Cap' category with a market capitalization of 42.08 B.Market Cap |
|
Edwards Lifesciences' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.18 | 0.10 | |
| Return On Capital Employed | 0.19 | 0.14 | |
| Return On Assets | 0.15 | 0.08 | |
| Return On Equity | 0.21 | 0.11 |
Determining Edwards Lifesciences' profitability involves analyzing its financial statements and using various financial metrics to determine if Edwards Lifesciences is a good buy. For example, gross profit margin measures Edwards Lifesciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Edwards Lifesciences' profitability and make more informed investment decisions.
Edwards Lifesciences' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Edwards Lifesciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edwards Lifesciences Corp. Check Edwards Lifesciences' Beneish M Score to see the likelihood of Edwards Lifesciences' management manipulating its earnings.
Evaluate Edwards Lifesciences' management efficiency
Edwards Lifesciences Corp has Return on Asset (ROA) of 0.1065 % which means that for every $100 of assets, it generated a profit of $0.1065. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1914 %, which means that it produced $0.1914 on every 100 dollars invested by current stockholders. Edwards Lifesciences' management efficiency ratios could be used to measure how well Edwards Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to 0.1 in 2024. Return On Capital Employed is likely to drop to 0.14 in 2024. At this time, Edwards Lifesciences' Intangibles To Total Assets are fairly stable compared to the past year. Fixed Asset Turnover is likely to climb to 4.91 in 2024, whereas Debt To Assets are likely to drop 0.06 in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 11.08 | 11.63 | |
| Tangible Book Value Per Share | 8.30 | 8.72 | |
| Enterprise Value Over EBITDA | 25.92 | 16.91 | |
| Price Book Value Ratio | 6.96 | 4.82 | |
| Enterprise Value Multiple | 25.92 | 16.91 | |
| Price Fair Value | 6.96 | 4.82 | |
| Enterprise Value | 43.3 B | 45.4 B |
Effective management at Edwards Lifesciences has been a driving force behind its market achievements. We assess the correlation between management practices and financial success to determine the stock's value.
Beta 1.12 |
Basic technical analysis of Edwards Stock
As of the 30th of November, Edwards Lifesciences shows the Downside Deviation of 1.5, coefficient of variation of 2229.89, and Mean Deviation of 1.17. Edwards Lifesciences Corp technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Edwards Lifesciences Corp information ratio, potential upside, as well as the relationship between the Potential Upside and kurtosis to decide if Edwards Lifesciences Corp is priced favorably, providing market reflects its regular price of 71.35 per share. Given that Edwards Lifesciences has jensen alpha of 0.0354, we urge you to verify Edwards Lifesciences Corp's prevailing market performance to make sure the company can sustain itself at a future point.Edwards Lifesciences' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edwards Lifesciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edwards Lifesciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Edwards Lifesciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Edwards Lifesciences' Outstanding Corporate Bonds
Edwards Lifesciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Edwards Lifesciences Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Edwards bonds can be classified according to their maturity, which is the date when Edwards Lifesciences Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| EDWARDS LIFESCIENCES P Corp BondUS28176EAD04 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand Edwards Lifesciences' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Edwards Lifesciences' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0394 | |||
| Market Risk Adjusted Performance | 0.3175 | |||
| Mean Deviation | 1.17 | |||
| Semi Deviation | 1.45 | |||
| Downside Deviation | 1.5 | |||
| Coefficient Of Variation | 2229.89 | |||
| Standard Deviation | 1.57 | |||
| Variance | 2.48 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | 0.0354 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.3075 | |||
| Maximum Drawdown | 8.56 | |||
| Value At Risk | (1.73) | |||
| Potential Upside | 2.42 | |||
| Downside Variance | 2.25 | |||
| Semi Variance | 2.1 | |||
| Expected Short fall | (1.17) | |||
| Skewness | 0.6687 | |||
| Kurtosis | 2.93 |
| Risk Adjusted Performance | 0.0394 | |||
| Market Risk Adjusted Performance | 0.3175 | |||
| Mean Deviation | 1.17 | |||
| Semi Deviation | 1.45 | |||
| Downside Deviation | 1.5 | |||
| Coefficient Of Variation | 2229.89 | |||
| Standard Deviation | 1.57 | |||
| Variance | 2.48 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | 0.0354 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.04) | |||
| Treynor Ratio | 0.3075 | |||
| Maximum Drawdown | 8.56 | |||
| Value At Risk | (1.73) | |||
| Potential Upside | 2.42 | |||
| Downside Variance | 2.25 | |||
| Semi Variance | 2.1 | |||
| Expected Short fall | (1.17) | |||
| Skewness | 0.6687 | |||
| Kurtosis | 2.93 |
Consider Edwards Lifesciences' intraday indicators
Edwards Lifesciences intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Edwards Lifesciences stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Edwards Lifesciences Corporate Filings
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
10Q | 6th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 24th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Edwards Stock media impact
Far too much social signal, news, headlines, and media speculation about Edwards Lifesciences that are available to investors today. That information is available publicly through Edwards media outlets and privately through word of mouth or via Edwards internal channels. However, regardless of the origin, that massive amount of Edwards data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Edwards Lifesciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Edwards Lifesciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Edwards Lifesciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Edwards Lifesciences alpha.
Edwards Lifesciences Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Edwards Lifesciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Edwards Lifesciences Corp Historical Investor Sentiment
Investor biases related to Edwards Lifesciences' public news can be used to forecast risks associated with an investment in Edwards. The trend in average sentiment can be used to explain how an investor holding Edwards can time the market purely based on public headlines and social activities around Edwards Lifesciences Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Edwards Lifesciences' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Edwards Lifesciences and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Edwards Lifesciences news discussions. The higher the estimate score, the more favorable the investor's outlook on Edwards Lifesciences.
Edwards Lifesciences Corporate Directors
| Paul LaViolette | Independent Director | Profile | |
| Leslie Heisz | Independent Director | Profile | |
| Steven Loranger | Independent Director | Profile | |
| Kieran Gallahue | Independent Director | Profile |
Additional Tools for Edwards Stock Analysis
When running Edwards Lifesciences' price analysis, check to measure Edwards Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edwards Lifesciences is operating at the current time. Most of Edwards Lifesciences' value examination focuses on studying past and present price action to predict the probability of Edwards Lifesciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edwards Lifesciences' price. Additionally, you may evaluate how the addition of Edwards Lifesciences to your portfolios can decrease your overall portfolio volatility.